Cambridge Cognition conjures gold from Ivory in Indian stunner

It has partnered with Ivory to scale early cognitive screening via CANTAB Pathway™ across the healthcare and consumer health markets in India.

The Cambridge neuroscience technology company specialises in digital cognitive assessments while Ivory is a venture-backed brain health company headquartered in Bengalaru, also known as Bangalore.

Of India's population of approximately 1.47 billion, estimates indicate that 138 million people are aged over 60 and as many as 34 million may be living with mild or major cognitive impairment

India's middle and affluent class, estimated to be 90-190 million people, is believed to have an increasing interest in longevity, healthspan and access to high-quality healthcare.

That all makes this partnership an important strategic step in Cambridge Cognition's expansion into high-growth international healthcare and consumer markets, leveraging Ivory's rapidly scaling brain health platform and distribution network.

Rob Baker, Chief Executive Officer of Cambridge Cognition, said: "India represents a major opportunity with a significant unmet need for earlier identification of cognitive impairment. As health-conscious, tech-enabled populations grow, demand for proactive brain health tools is increasing rapidly.

"We believe the Ivory team shares our passion and energy to make a difference and has made impressive progress across both consumer and professional healthcare markets. We are excited to partner with them to expand access to CANTAB Pathway™ in India."

Ivory recently published India's first-of-its-kind Brain Health Report, providing new insights into the country's cognitive wellbeing landscape. Multiple studies suggest that up to 90 per cent of cognitive impairment remains underdiagnosed, highlighting a substantial unmet need for scalable early screening solutions.

With no definitive cure for neurodegenerative conditions like dementia, prevention and early identification are increasingly critical. Ivory's mission is to shift the focus from late-stage diagnosis to proactive brain health management through neuroscience-based digital assessments, enabling individuals to take action before symptoms escalate.

Issac John, Chief Executive Officer at Ivory, said: "Our founding scientists have known and used CANTAB for many years. We appreciate the strong scientific pedigree of the assessments based on thousands of clinical peer-reviewed papers.

"The Cambridge Cognition team have built CANTAB Pathway™ to be exactly the product we need to add to our offering to enable us to pursue our mission of shifting the focus from late-stage diagnosis to proactive brain health solutions."

India has an expanding middle and affluent class, with an estimated 90-190 million people for whom longevity, healthspan, and access to high-quality healthcare are growing priorities. In parallel, younger urban populations are increasingly tech-enabled and motivated to manage their health through monitoring and lifestyle choices.

Dr. Sumiti Saharan, Chief Scientific Officer, Ivory, said: "Early cognitive screening is one of the most powerful ways to change trajectories in neurodegenerative conditions, where intervention often begins only after cognitive decline has already advanced.

"In India, under diagnosis of cognitive impairment remains a significant gap. Scalable, validated digital tools such as CANTAB Pathway™ offer an opportunity to standardise assessment, enable earlier identification and empower clinicians to intervene at a stage when it can make the greatest difference."

This strategic partnership between Cambridge Cognition and Ivory offers high accuracy, low burden of administration and real-time results that are essential to improving early identification of cognitive impairment and supporting brain health at scale.

Ivory intends to deploy CANTAB Pathway™ at scale across both professional healthcare and consumer health segments in India, leveraging its established and growing clinical network, consumer-facing platform, and partnerships across hospitals, clinics, and diagnostic and health-tech ecosystems to expand access to early cognitive screening. These flagship assessments are currently available in English and multiple languages including Hindi, Tamil, Telugu, Bengali and Kannada, with further language expansion planned.